
|Videos|November 5, 2013
The Utility of Afatinib in Lung Cancer
Author(s)Tony S.K. Mok, BMSc, MD, FRCPC
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses the utility of afatinib in patients with lung cancer.
Advertisement
Clinical Pearls
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses the utility of afatinib in patients with lung cancer.
- Results from the LUX-Lung 3 trial demonstrated benefit with afatinib compared with cisplatin/pemetrexed in patients with advanced lung adenocarcinoma withEGFRmutations
- Afatinib is now available in the U.S.
- How afatinib compares with other TKIs is still up for debate
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Gut Health & Myeloma: How Bacteria May Predict Transplant Success With Pooja Phull, MD
5










































